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The present report describes a vaccine-induced thrombotic thrombocytopenia (VITT) case with 
fatal exacerbation after initial improvement following initial IVIg administration and 
anticoagulation. An 83-year-old woman presented at the emergency room with an alteration of 
her general condition. She presented with symptoms of weakness, nausea, vomiting, weight loss 
and spontaneous bruises without any obvious reason, 14 days after having received her first dose 
of ChadOx1 nCov-19. According to our medical records, she did not receive heparin or 
derivative during the last four months. Clinical examination unraveled bruising on the upper 
limbs. Computer Tomography (CT) of thorax and abdomen was normal. Oxygen saturation was 
98% at admission and the patient was tested negative for SARS-CoV-2 infection as assessed by 
reverse-transcriptase polymerase chain reaction (RT-PCR). The initial laboratory investigations 
on the day of admission revealed that the patient was suffering from marked thrombocytopenia 
(i.e. platelet count of 10,000 per mm3), dramatically increased D-dimers plasma levels (i.e. > 
20,000 ng/mL) and slightly low plasma fibrinogen (i.e. 179 mg/dL) (Figure 1). She was 
transfused with a platelet concentrate (roughly 3.5x1011 platelets) on the day of admission.  
During the night, she suffered from dyspnea grade NYHA 4. Pulmonary ventilation and 
perfusion (V/Q) scan was performed and disclosed bilateral pulmonary embolism. Anti-PF4 IgG 
antibodies (i.e. 1.80 AU/mL, Figure 1) were detected on day 1 post-admission using a 
PF4/polyvinylsulfonate rapid assay (HemosIL® AcuStar HIT IgG assay, Instrumentation 
Laboratory Belgium NV, Zaventem, Belgium). The diagnosis of VITT was confirmed using a 
heparin-induced multi-electrode aggregometry method.(1) In face of the clinical picture, i.e. 
thrombocytopenia and thrombosis, with the presence of anti-PF4 antibodies and positive platelet 
activation tests within 30 days after vaccination with ChadOx1 nCov-19, VITT was 
diagnosed.(2) The patient therefore promptly received 15 grams of IVIg (Privigen®, CSL 
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Behring Gmbh, Marburg, Germany) and methylprednisolone 1 mg/kg. A second platelet 
concentrate (roughly 4.5x1011 platelets) was administered for allowing initiation of 
anticoagulation as platelet count was still below 30,000 per mm3.(3) Platelet count rapidly 
improved, i.e. 53,000 per mm3, and anticoagulation was started with fondaparinux 5 mg od 
subcutaneously from day 1 to day 3 (taking into account renal failure, i.e. Cockcroft-Gault 
creatinine clearance < 50 mL/min). She received additional IVIg on day 2 and 3, at the dose of 
60 grams per day for a total IVIg dose of 135 grams corresponding to 1.7 grams of IVIg per kg 
administered over a period of 48 hours. Fondaparinux dose was increased to 7.5 mg od from day 
4 to day 11 since renal function improved. On day 6, the patient was stabilized, and her global 
health status was improved as witnessed by normalized platelet count, decrease in D-dimers (i.e. 
from > 20,000 ng/mL at admission to 14,380 ng/mL) and CRP (from 145 mg/dL at admission to 
23 mg/dL). Later that day, however, oxygen saturation dropped below 80%. Cough with sputum 
production was noted and exacerbation of COPD with Moraxella catarrhalis infection was 
diagnosed. Oxygen supplementation was then started (2 liters per minute) combined with oral 
moxifloxacin 400 mg od for 5 days. On day 12 post-admission, anticoagulation was switched 
from fondaparinux to apixaban 5 mg bid. 
Unfortunately, the clinical status worsened on day 12 post-admission with a de novo reduction of 
platelet count. Abdominal CT scan showed right adrenal hematoma with left adrenal infiltrate, 
which is a usual presentation of adrenal infarction, as described in auto-immune heparin-induced 
thrombocytopenia and also recently in VITT.(4, 5) Four units of 500 IU/mL of prothrombin 
complex concentrate were administered on day 14 as an attempt to control the adrenal 
hematoma, but she died later that day from hypovolemic shock probably secondary to adrenal 
hemorrhage. A causal adrenal infarction may have existed but could not be confirmed as neither 
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an injected CT scan nor an autopsy was performed. Nevertheless, adrenal insufficiency was not 
documented and cortisol levels on day 14 was still in the upper range (i.e. 21 µg/dL, normal 
range: 6.2 to 18 µg/dL). Moreover, it must be noted that although apixaban was last administered 
on day 13 in the morning and never reintroduced, its plasma level on day 14 was 353 ng/mL 
(usual Ctrough range: 22 to 177 ng/mL) and was still 132 ng/mL on day 15. The accumulation of 
apixaban may thus have contributed to, or even triggered, this bleeding event.  The initial 
infusion of platelet concentrates may also have contributed to disease progression, as well as to 
the pulmonary embolism observed at diagnosis. An immediate treatment with IVIg, as now 
recommended by the American Society of Hematology,(6) could have been beneficial but the 
presence of active bruising, the absence of documented thrombosis and the marked 
thrombocytopenia guided our therapeutic choice at that time. This case further highlights how 
VITT is a dynamical condition, which should not be discounted in a recently vaccinated patient 
with only thrombocytopenia and increased D-dimer levels, even in the absence of documented 
thrombosis, and that IVIG should be considered promptly, along with anti-PF4 testing and 
thrombosis screening. 
The rapid fatal outcome, occurring two weeks after VITT diagnosis while an improvement was 
noticed, raised the question of an early relapse or an exacerbation of the initial event. In an 
attempt to understand the possible cause(s), additional laboratory investigations were performed, 
as reported in Figure 1. Blood samples collected post-admission on day 1 (diagnosis), day 4 
(after IVIg administration), day 7 (marked clinical improvement with platelet count 
normalization) and day 15 (deterioration of patient’s status, leading to death) were selected to 
assess time-related changes of anti-PF4 antibodies, platelet activation with PF4-SRA (7) and 
total IgG levels. 
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Result of the enzyme-linked immunosorbent assay (ELISA) with immobilized PF4/PVS 
complexes (LIFECODES PF4 IgG, Immucor Lifecodes, Jette, Belgium) remained strongly 
positive during the whole hospital stay with OD > 3.00 measured with all samples collected from 
day 1 to day 15. Positive results were also obtained using a modified in-house ELISA in which 
the wells are only coated by PF4 (8), demonstrating the presence of IgG antibodies that bound 
PF4 alone (data not shown). Such characteristics of VITT antibodies, shared with those of highly 
pathogenic auto-immune HIT antibodies (9), indicate a different specificity and affinity towards 
PF4 compared to classical HIT antibodies, and explain why their detection by HIT-dedicated 
immunoassays may be inadequate.(7) The fact that anti-PF4 IgG antibodies were detected using 
a PF4/polyvinylsulfonate rapid assay (HemosIL® AcuStar HIT IgG assay) is particular since this 
assay failed to detect anti-PF4 antibodies in most of reported VITT cases. Nevertheless, the 
HemosIL® Acustar HIT IgG assay may rarely give weak positive results in patients with likely 
VITT diagnosis, as stated by Platton et al., who reported 2 positive results out of 31 patients, all 
of whom had anti-PF4 IgG detected by ELISA.(10)  
PF4-SRA was performed with the same samples, as previously described.(7) Platelet activation, 
measured through maximal serotonin release, was 90% in absence of heparin on day 1, decreased 
by more than 50% after IVIg administration (day 4, 35%) and remained low when the patient 
was getting better (day 7, 36%). In contrast, platelet activation returned to a high level at the time 
of clinical deterioration, day 15 (79%). Time related changes of total IgG plasma levels mirrored 
those of PF4-SRA (Figure 1). While total IgG level was rather low at diagnosis, it rose above 30 
g/L after IVIg administration and then rapidly decreased, as observed on day 15, with a return to 
normal values for a healthy adult. These data support the hypothesis that the rebound of platelet 
activation observed in PF4-SRA at the time of clinical deterioration could be due to a rapid 
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elimination of the infused immunoglobulins and the loss of their competing effect with platelet 
activating anti-PF4 antibodies on platelet Fc RIIa.  
Additional experiments were performed with PF4-SRA to consolidate our hypothesis that the 
levels of IgG can explain the exacerbation The same samples were diluted either in normal 
plasma (containing normal IgG level) or in modified Tyrode’s buffer at 1/10, 1/20, 1/40 dilution 
ratios. When samples were diluted in normal plasma, platelet activation decreased proportionally 
with the dilution, and was completely abolished at 1/40, except for the day 1 sample, which still 
slightly activate platelets under these conditions (Figure 2). In contrast, when the samples were 
diluted in Tyrode’s buffer, platelet activation remained high (near 100%) for the samples 
collected on day 1 and day 15 but increased for those obtained at days 5 and 7, approaching 
100% (Figure 2). These results strongly support that platelet activation by VITT antibodies was 
inhibited by normal IgG, and that lowering the concentrations of normal IgG led to the 
reappearance of platelet activation by loss of competition between the IVIg and anti-PF4 IgG. 
This case supports the concept that a proper monitoring using an appropriate functional assay 
could help in clinical decision making since PF4-SRA mirrored with the clinical evolution of the 
patient. Such observation has also been made in a recent study, which demonstrated that platelet 
activation by VITT antibodies was inhibited in patients treated with IVIg.(11) Nevertheless, this 
needs to be confirmed. Interestingly, the inhibitory effect of normal polyclonal IgG on the 
platelet activation induced by PF4-specific antibodies could also vary from one patient to 
another, as previously demonstrated in HIT patients.(12) It is also important to note that 
administration of IVIg reduces the activation of platelets as assessed by the PF4-SRA. This has 
major consequences when collecting samples for confirmation of VITT diagnosis and dilution in 
appropriate buffer, as we did in our experiments, could be recommended to assess the 
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competitive interaction between anti-PF4 IgG and IVIg. However, this test lacks worldwide 
availability, and cannot easily be used for emergency patients monitoring. Therefore, as total IgG 
concentration measured in the patient inversely correlated with platelet activation in PF4-SRA, 
quantitatively assaying anti-PF4 IgG antibodies levels and total IgG concentration in the 
patient’s plasma could help in identifying situations where the competition between normal 
polyclonal IgG and anti-PF4 IgG on Fc RIIa may switch in favor of the platelet activating 
antibodies.(13)  
Despite data on IVIg clearance parameters and target concentrations are lacking for such a very 
peculiar condition, a rapid decrease in total IgG concentrations within the normal range (i.e. 7-16 
g/l) (14) could alert to possible therapeutic escape, and the need for re-administration of IVIg, 
especially in situation where anti-PF4 IgG remains high. In the patient, total IgG concentration 
was divided by two within eight days, which is pretty faster than the median half-life of 30 days 
generally reported in the literature for IVIg.(15) Although further studies are needed to 
understand that accelerated clearance and assess clinical relevance of total IgG measurement to 
monitor the efficacy of IVIg, it appears a very affordable tool in practice in combination with 
anti-PF4 IgG antibodies testing. 
Informed consent and ethical committee approval: 
As the patient died, an independent review board of the Clinique Sainte-Elisabeth CHU UCL Namur 
(OM070) has been consulted to decide if the reporting of this case is ethically acceptable. This ethical 
committee (decision number: 27-21) was favorable to the publication of this case and did not see any 
ethical issue in publishing this case-report. All the data has been anonymized.
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Figure 1: Clinical and laboratory data of the case.  
Figure 2: Dilution experiments on samples collected at day 1 post-admission (diagnosis), days 4 
post-admission (after IVIg administration), day 7 post-admission (marked clinical improvement 
with platelet count normalization) and day 15 post-admission (deterioration of patient’s status and 
death). Dilutions were made in normal heated plasma (containing normal IgG level) or in modified 
Tyrode’s buffer at 1/10, 1/20, 1/40 dilution ratios. Platelet activation was assessed without heparin in 
PF4-SRA and results are expressed in percentage of serotonin release. 
 


